The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
News  >  

Ibrutinib and Palbociclib Combination Active in Previously Treated MCL

Darcy Lewis
Published Online:8:59 PM, Mon February 18, 2019

Peter Martin, MD

The combination of ibrutinib (Imbruvica) and palbociclib (Ibrance) appeared to be a feasible and active treatment regimen in patients with previously treated mantle cell lymphoma (MCL), according to findings from a phase I dose-finding study recently published in Blood. 1

“In this study, we found that the combination of ibrutinib and palbociclib was feasible and active…. We [also] found that responders to ibrutinib-based combinations had a low rate of treatment failure,” the authors, led by Peter Martin, MD, of Meyer Cancer Center, Weill Cornell Medicine, New York, wrote. “Although BTK inhibitor-based combinations appear promising, the degree to which they improve upon single-agent ibrutinib is unclear…. randomized trials will be required to define the true impact on efficacy and safety.”

This study grew out of the authors’ explorations of the fact that nearly half of all MCL patients who receive ibrutinib monotherapy experience treatment failure during the first year. “We previously demonstrated that prolonged early G1 cell cycle arrest induced by the oral, specific CDK4/6 inhibitor palbociclib can overcome ibrutinib resistance in primary human MCL cells and MCL cell lines expressing wild-type BTK,” they wrote.

Martin et al set out to identify the combination’s recommended dose for a phase II trial, which is now ongoing. Their secondary objectives were to explore the regimen’s toxicity and activity profiles.

They enrolled 27 patients who had previously been treated for MCL. Other inclusion factors were good ECOG performance status and adequate function in bone marrow and other organs. Patients who had previously been treated with BTK or CDK4/6 inhibitors were excluded.

Treatment consisted of ibrutinib administered daily and palbociclib administered for 21 days of each 28-day cycle as follows:
 
Level Ibrutinib Palbociclib Number of patients
Level 1 280 mg 75 mg 3
Level 2 420 mg 75 mg 3
Level 3 420 mg 100 mg 6
Level 4 560 mg 100 mg 10
Level 5 560 mg 125 mg 5

Treatment continued until patients’ disease progressed, toxicities became unacceptable, or they withdrew from the trial.

Martin et al identified the maximum tolerated dose as level 4, ibrutinib 560 mg, and palbociblib 100 mg. At dose level 5, 2 of 5 patients developed grade 3 rash as the dose-limiting toxicity (DLT). One patient experienced DLT at dose level 3, with grade 4 neutropenia that lasted more than 7 days.

Numerous grade 3 to 4 toxicities occurred, including neutropenia (41%), thrombocytopenia (30%), anemia (15%), hypertension (15%), febrile neutropenia (15%), and lung infection (11%). Additionally, 2 patients apiece experienced upper respiratory tract infection (7%), fatigue (7%), increased ALT/AST (7%), rash (7%), hyperglycemia (7%), and myalgia (7%).

Other notable adverse events (AEs) included grade 1 reactivation of viral hepatitis, grade 2 Clostridium difficile infection, grade 3 varicella zoster viral encephalitis, grade 3 influenza A infection, grade 3 atrial fibrillation, grade 3 decreased ejection fraction, grade 3 pneumonitis, and grade 4 gastric hemorrhage. Each of these occurred in 1 patient apiece.

A total of 4 patients required dose interruptions. Eight patients required a dose reduction while on treatment, mostly due to cytopenias.

With a median follow-up of 25.6 months, 2-year progression-free survival (PFS) was 59.4% (95% CI, 37.9-80.9). Two-year overall survival (OS) was 60.6% (95% CI, 41.1-80.1).

The authors found no association between PFS and MIPI score, Ki67, or response to last therapy. Eleven patients have died, including 9 deaths related to MCL. Additionally, 1 patient died from complications of allogeneic stem cell transplantation, and 1 died of unknown causes unrelated to MCL or study treatment. The median survival following disease progression was 5 months.

Eighteen patients (67%) responded to treatment; 10 of these patients achieved complete responses (CR; 37%).

Nine patients had not had a documented response to their most recent previous therapy. Of these, 2 patients achieved a CR and 1 achieved a PR. Among 7 patients with a Ki67 >30%, 5 responded, including 3 patients with a CR. Among 7 patients with a high-risk MIPI score, 4 responded. One of these patients had a CR.

Martin et al noted that, despite the apparent durability of responses, “the overall response rate of 67% was similar to the response rate reported in the phase II pivotal trial with single-agent ibrutinib. A comparable experience was noted in the trial of ibrutinib, lenalidomide, and rituximab, which reported a response rate of 76% (CR 56%) and the trial of ibrutinib plus venetoclax, which reported a response rate of 71% (CR 60%),” they wrote. “Like both of those studies, we found that responders to ibrutinib-based combinations had a low rate of treatment failure, but the roughly one-third of patients with primary BTK inhibitor resistance appear unlikely to be served by BTK inhibitor-based combinations.”2-4

They recommend that clinicians seek out clinical trials for patients with BTK inhibitor resistance.
 
 
References:
  1. Martin P, Bartlett NL, Blum KA, et al. A phase I trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. Published online January 28, 2019. DOI 10.1182/blood-2018-11-886457.
  2. Wang ML, Rule S, Martin P, et al. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2013;369(6):507-516.
  3. Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, singlearm, phase 2 trial.
  4. Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus Venetoclax for the Treatment of
    Mantle-Cell Lymphoma. N Engl J Med. 2018;378(13):1211-1223.


Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.